Deutsche Bank AG Takes Position in Nurix Therapeutics, Inc. $NRIX

Key Points

• Deutsche Bank acquired 151,453 shares of Nurix Therapeutics in the second quarter, valued at approximately $3.67 million and representing a 0.15% stake.
• Company insiders sold 25,314 shares worth $589,361 over the past 90 days, including sales by the CFO and another insider under pre-arranged Rule 10b5-1 plans.
• Nurix shares opened at $26.95, near their 12-month high, while analysts maintained a generally positive outlook with a “Moderate Buy” consensus and an average price target of $34.21. The company nevertheless missed its latest earnings and revenue estimates.

Deutsche Bank AG bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 151,453 shares of the company's stock, valued at approximately $3,674,000. Deutsche Bank AG owned 0.15% of Nurix Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Larson Financial Group LLC raised its holdings in Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company's stock worth $29,000 after purchasing an additional 1,190 shares during the period. California State Teachers Retirement System lifted its holdings in Nurix Therapeutics by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 68,019 shares of the company's stock worth $1,290,000 after acquiring an additional 1,476 shares in the last quarter. Intesa Sanpaolo Wealth Management bought a new position in Nurix Therapeutics during the fourth quarter worth about $31,000. Royal Bank of Canada grew its stake in Nurix Therapeutics by 17.6% in the fourth quarter. Royal Bank of Canada now owns 10,842 shares of the company's stock valued at $206,000 after acquiring an additional 1,623 shares during the period. Finally, Arizona State Retirement System increased its holdings in shares of Nurix Therapeutics by 8.2% in the fourth quarter. Arizona State Retirement System now owns 21,990 shares of the company's stock worth $417,000 after acquiring an additional 1,674 shares in the last quarter.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 4,761 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total value of $115,977.96. Following the transaction, the chief financial officer owned 40,166 shares in the company, valued at $978,443.76. The trade was a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the company's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00. Following the sale, the insider directly owned 117,227 shares in the company, valued at $2,930,675. This trade represents a 3.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 25,314 shares of company stock worth $589,361. Company insiders own 6.70% of the company's stock.

Nurix Therapeutics Stock Up 2.6%

NASDAQ:NRIX opened at $26.95 on Wednesday. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of -7.81 and a beta of 1.79. Nurix Therapeutics, Inc. has a twelve month low of $8.19 and a twelve month high of $28.23. The stock's 50 day moving average price is $23.82 and its two-hundred day moving average price is $18.79.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The firm had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on NRIX. Needham & Company LLC reissued a "buy" rating and set a $34.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, August 4th. Robert W. Baird lifted their price target on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the company an "outperform" rating in a research note on Thursday, June 18th. UBS Group upped their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, July 22nd. Oppenheimer started coverage on shares of Nurix Therapeutics in a research report on Monday, June 29th. They set an "outperform" rating and a $28.00 price objective for the company. Finally, BTIG Research restated a "buy" rating and set a $32.00 price objective on shares of Nurix Therapeutics in a report on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Nurix Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $34.21.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company's pipeline includes multiple programs in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source